BioAge Labs, Inc. (BIOA)
- Sector
- Pharmaceuticals
- Last price
- $5.34
- As of
Kresmion compiles this page from BIOA's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
BioAge Labs, Inc. (BIOA): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-05.
See the full BIOA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for BIOA on one page. Preview it with sample data, then open it live with a free account.
Preview the BIOA dossierActive events for BIOA
- mediumEarnings below estimates
Q3-2026: Missed consensus by 13.4%, EPS $-0.73 vs $-0.6438 estimate
- high13F: funds added
3 tracked funds increased BIOA this 2026Q2, institutional consensus
- high13F: large reduction
CITADEL ADVISORS LLC cut 78% of BIOA (2026Q2)
- high13F: large reduction
CITADEL ADVISORS LLC cut 81% of BIOA (2026Q2)
- high13F: large reduction
MILLENNIUM MANAGEMENT LLC cut 94% of BIOA (2026Q2)
FREE, NO ACCOUNT
Every event on BIOA, as it fires
You are seeing 5 of 13 events recorded on BIOA since 2026-06-10.
The five above landed across 3 days. The other 8 were recorded on 3 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
BIOA positions held by the managers we follow (2026Q2)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| D. E. Shaw & Co., Inc. FundCUSIP 09077V100 · 2026Q2 | $18.2M | 0.01% |
| MILLENNIUM MANAGEMENT LLC FundCUSIP 09077V100 · 2026Q2 | $5.5M | 0.00% |
| RENAISSANCE TECHNOLOGIES LLC FundCUSIP 09077V100 · 2026Q2 | $4.1M | 0.01% |
| CITADEL ADVISORS LLC FundCUSIP 09077V100 · 2026Q2 | $1.9M | 0.00% |
| TWO SIGMA INVESTMENTS, LP FundCUSIP 09077V100 · 2026Q2 | $1.5M | 0.00% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, BIOA
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
More data on BIOA
BIOA against its peers
BIOA's operating margin of -1031.5% ranks in the 8th percentile of 18 Pharmaceuticals sub-industry peers, fiscal periods ending between 2025-03-31 and 2026-06-30.
| Metric | BIOA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 9.0M USD | 403M USD | 18 | 19 |
| Gross margin | n/a | 73.3% | n/a | 11 |
| Operating margin | -1031.5% | 10.6% | 8 | 18 |
| Net margin | -896.1% | 0.7% | 8 | 18 |
| Return on equity | -29.6% | -6.5% | 37 | 22 |
| P / E | n/a | 14.0x | n/a | 9 |
Peers (25): FULC, SIGA, ACB, AVIR, ACRS, COLL, ESPR.D, ANRO, ALMS, AMPH, OMER, NKTR, INVA, OCUL, PLRX, PCRX, GPCR, PAHC, ANIP, NUVB, TRVI, HRMY, XERS, SUPN, BHC. Fiscal periods ending between 2025-03-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (BIOA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in BIOA on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on BIOA in the last 180 days.
Upstream: SEC EDGAR filings for BIOA
Kresmion, "BioAge Labs, Inc. (BIOA) institutional holdings and SEC filings", data as of 2026-11-08, https://kresmion.com/research/BIOA. Upstream data: SEC EDGAR filings for BIOA.
Link to this data (HTML):
<a href="https://kresmion.com/research/BIOA">BioAge Labs, Inc. (BIOA) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow BIOA on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to BIOA for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.